Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN− glioblastoma <i>in vivo</i>

26 Mar 2016

Abstract excerpt

// Wen Xu 1, 2 , Yanyu Bi 2 , Juan Kong 2 , Jiqin Zhang 2 , Biao Wang 2 , Kesang Li 2 , Mi Tian 2 , Xiaorong Pan 2 , Bizhi Shi 2 , Jianren Gu 2 , Hua Jiang 2 , Xianming Kong 3 , Zonghai Li 2 1 Medical School of Fudan University, Shanghai, China 2 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China 3 Renji...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27029073
DOI: 10.18632/oncotarget.8407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN− glioblastoma <i>in vivo</i>PMID 27029073Read ↗

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical EvidenceSemantic proximity Read ↗

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Semantic proximity Read ↗

Targeted Molecular Therapy of GBMSemantic proximity Read ↗

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapySemantic proximity Read ↗

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKTSemantic proximity Read ↗

Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapySemantic proximity Read ↗

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitorsSemantic proximity Read ↗

The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastomaSemantic proximity Read ↗

Targeting the AKT Pathway in GlioblastomaSemantic proximity Read ↗

Combined EGFR and Autophagy Modulation Impairs Cell Migration and Enhances Radiosensitivity in Human Glioblastoma CellsSemantic proximity Read ↗

The glioblastoma suppression effect of recombinant Newcastle disease virus harboring the PTEN gene delivered intravenously to a U87 MG PTEN mutant glioblastoma cell-bearing orthotropic mouse modelSemantic proximity Read ↗

The effect of miR‐579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.